GnRH analogue for the prevention of ovarian hyperstimulation syndrome: a pilot study.
Continuation of GnRH analogue after ovum retrieval produces a faster decline in vascular endothelial growth factor levels and ascitis in women at risk of ovarian hyperstimulation syndrome.
Giles
Juan
J
IVI Madrid, Calle Santiago de Compostela 88, Madrid, Spain. jgiles@ivi.es
Requena
Antonio
A
García-Velasco
Juan Antonio
JA
Pacheco
Alberto
A
Pellicer
Jorge
J
Pellicer
Antonio
A
D000328:Adult; D001201:Ascites / Q000517:prevention & control; D006063:Chorionic Gonadotropin / Q000009:adverse effects / Q000494:pharmacology; D004311:Double-Blind Method; D004958:Estradiol / Q000097:blood; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D006801:Humans; D008186:Luteolytic Agents / Q000627:therapeutic use*; D054315:Oocyte Retrieval / Q000379:methods; D016471:Ovarian Hyperstimulation Syndrome / Q000097:blood / Q000517:prevention & control*; D010060:Ovulation / Q000187:drug effects; D010062:Ovulation Induction / Q000379:methods*; D010865:Pilot Projects; D011446:Prospective Studies; D012307:Risk Factors; D017329:Triptorelin Pamoate / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
D006063:Chorionic Gonadotropin; D008186:Luteolytic Agents; D042461:Vascular Endothelial Growth Factor A; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; C062876:cetrorelix